Household International's board, advised by investment bankers and counsel, studied the increasing prevalence in the mid-1980s of hostile, often coercive, two-tier tender offers that pressured shareholders to tender into a front-end premium for fear of a less favorable back-end. In response, and without a specific hostile bid pending, the board approved a shareholder rights plan. The plan distributed, as a dividend, one right for each outstanding share of common stock. The rights were not immediately exercisable. They would become exercisable upon the earlier of (i) a public announcement that any person had acquired a significant percentage (e.g., 20%) of Household's outstanding common stock (a flip-in trigger), or (ii) the commencement of a tender or exchange offer that, if consummated, would result in such ownership (often framed around a higher threshold, e.g., 30%). Upon a triggering event, each right (other than those owned by the triggering acquirer) entitled its holder to purchase shares at a substantial discount, causing dilution to the acquirer. If, after a triggering acquisition, Household were merged or combined with the acquirer, the rights would flip over to allow holders to purchase the acquirer's stock at a discount. The board retained the authority to redeem the rights for a nominal amount prior to the trigger and to exchange rights under certain conditions. Moran, a Household director and stockholder who opposed the plan, sued in the Delaware Court of Chancery seeking a declaration that the plan was invalid under the Delaware General Corporation Law (DGCL) and a breach of fiduciary duty. The Court of Chancery upheld the plan's facial validity, and Moran appealed to the Delaware Supreme Court.
Does a Delaware corporation's board of directors have authority under the DGCL to adopt a shareholder rights plan (poison pill) without shareholder approval, and is such adoption a valid exercise of fiduciary duty on its face absent a specific takeover bid?
Under DGCL § 141(a), a corporation's business and affairs are managed by or under the direction of the board of directors. DGCL § 157 authorizes boards to create and issue rights and options entitling the holders to purchase stock upon terms fixed by the board. The adoption of a shareholder rights plan falls within these statutory powers, subject to directors' fiduciary duties. When a defensive measure is adopted in the face of or in anticipation of takeover activity, the board's conduct is evaluated under the fiduciary framework that includes the business judgment rule and, where applicable, Unocal's enhanced scrutiny: the board must show reasonable grounds for believing a danger to corporate policy and effectiveness exists and that the defensive response is reasonable and proportionate (i.e., not coercive or preclusive). The plan's legality is assessed facially at adoption, while its future application to a particular bid may be separately scrutinized under Unocal and related precedents.
Yes. The Delaware Supreme Court held that the DGCL authorizes a board to adopt a shareholder rights plan without shareholder approval and that Household's plan was facially valid. The court further held that the board acted within its fiduciary obligations in adopting the plan on a preemptive basis; any later use of the plan against a specific offer would be subject to Unocal's enhanced scrutiny.
Statutory authority: The court read DGCL § 157 to confer broad authority on boards to create and issue rights and options on terms the board sets, and § 141(a) to vest primary managerial power in the board. A poison pill is, at bottom, a set of rights attached to shares that becomes exercisable upon specified events. Nothing in the DGCL or Household's governing documents prohibited issuing such rights, and the plan's mechanics (including redemption and exchange features) were within § 157's ambit. Shareholder rights and transferability: The plaintiff argued the pill impermissibly restricted shareholder voting and the ability to accept tender offers. The court disagreed, emphasizing that the plan did not bar proxy contests or prevent shareholders from voting to replace the board with directors who could redeem the rights. Nor did the plan impose an absolute restraint on share transfer; rather, it altered economic incentives if a triggering threshold were crossed. Because the board retained the ability to redeem the rights and a bidder could seek control through a proxy fight, the plan was not inherently coercive or preclusive on its face. Fiduciary review: The board adopted the plan after deliberation and professional advice, identifying a credible threat from then-prevalent coercive, two-tier offers. The court concluded the adoption was a good faith, informed response intended to force would-be acquirers to negotiate with the board, thus enhancing the board's leverage to protect the corporation and its stockholders. The court applied the business judgment rule to the adoption decision but made clear that if the pill were later used to resist a specific bid, the board's actions would be reviewed under Unocal's enhanced scrutiny to ensure the response remained reasonable in relation to the threat and was neither coercive nor preclusive.
Moran is the foundational case validating poison pills under Delaware law. It entrenched the board's statutory authority to adopt rights plans without shareholder approval and framed how fiduciary duties constrain both adoption and use. The decision catalyzed widespread adoption of pills and, together with Unocal, created the modern analytic sequence: boards may adopt a pill proactively; the pill is facially valid; and any deployment against a live bid must satisfy enhanced scrutiny (and, where control sale becomes inevitable, Revlon duties). For students, Moran illuminates statutory interpretation (DGCL §§ 141 and 157), the limits of shareholder autonomy in tender contexts, and the doctrinal interplay between business judgment deference and takeover-specific scrutiny.
Moran v. Household International established that Delaware boards can, consistent with statutory authority, adopt shareholder rights plans without a shareholder vote and that such plans are facially valid defensive tools. The decision underscores that the pill's core function is to create negotiating leverage and deter coercive tactics, not to permanently entrench management.